Drug Shortages Give Ben Venue Relief In FDA Consent Decree
This article was originally published in The Gold Sheet
The consent decree permits the company to continue to manufacture more than 100 drugs, 20 of which are on FDA’s current drug shortage list. Ben Venue must prove compliance with good manufacturing practice requirements before it can manufacture its other drugs.
You may also be interested in...
Rapid approval of a new, preservative-free generic methotrexate and permission to import an unapproved version of doxorubicin touted at press conference as FDA emphasizes the success of administrative efforts.
During nine years at Ben Venue, Gaugh was responsible for strategic planning, financial management, business development, marketing and sales for the company’s $500 million branded generic injectable business, which is now struggling with manufacturing challenges.
Operation Warp Speed confirmed the necessity of having a facility on hand to develop and manufacture a vaccine for the next crisis, the outgoing advisor says.